Vol. 3 No. 11 (2023)
Reimbursement Reviews

Nelarabine (Atriance)

Published November 24, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses nelarabine (Atriance), 5 mg/mL solution for IV infusion.
  • Indication: Nelarabine (Atriance) is indicated for the treatment of patients with T-ALL and T-LBL whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens.